Prof Stephen Schuster speaks to ecancer at the 2019 ASH meeting in Orlando about the use of mosunetuzumab in patients with non-Hodgkin lymphoma.
He describes the design of this study, along with the results achieved and toxicities observed with the action of this dual-targeting antibody.
Prof Schuster elaborates on this unmet need for patients who do not respond to CAR T-cell therapy.
He concludes by discussing the future use of this drug which is easily accessible due to its off-the-shelf availability.
Watch the press conference here.
Read more about the study here.